So far in 2014 the European medicines agency's committee for medicinal products for human use (CHMP) has returned four negative opinions for new medicines compared to 16 positive recommendations. However, all four companies who have been unsuccessful with the committee in the New Year have this month called for re-examinations of the decisions.
First up for a re-examination by the CHMP is Novartis for its acute heart failure treatment serelaxin (RLX030).






![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
